• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by STERIS plc (Ireland)

    8/11/25 5:09:13 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001293588
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    STERIS plc
    SEC File Number
    001-38848
    Address of Issuer
    70 SIR JOHN ROGERSON'S QUAY
    DUBLIN
    IRELAND
    2
    Phone
    35312322000
    Name of Person for Whose Account the Securities are To Be Sold
    Sohi Mohsen
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Ordinary
    Charles Schwab & Co., Inc.
    3000 Schwab Way
    Westlake � TX � 76262
    4110994450.009849060608/11/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Ordinary08/11/2025Employee Stock Option ExerciseSTERIS plcCheckbox not checked411008/11/2025Broker Payment for Cashless Exercise

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/11/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    MOHSEN SOHI

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $STE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    7/15/2025$276.00Equal-Weight → Overweight
    Morgan Stanley
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    More analyst ratings

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Steris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Steris from Equal-Weight to Overweight and set a new price target of $276.00

    7/15/25 8:30:16 AM ET
    $STE
    Industrial Specialties
    Health Care

    Jefferies initiated coverage on Steris with a new price target

    Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

    5/29/25 8:18:41 AM ET
    $STE
    Industrial Specialties
    Health Care

    Steris upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

    10/24/24 6:28:31 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Breeden Richard C exercised 4,110 units of Ordinary Shares at a strike of $64.05, increasing direct ownership by 13% to 36,664 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    8/15/25 4:31:11 PM ET
    $STE
    Industrial Specialties
    Health Care

    Director Sohi Mohsen exercised 4,110 units of Ordinary Shares at a strike of $64.05 and sold $994,456 worth of Ordinary Shares (4,110 units at $241.96) (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    8/12/25 5:28:02 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Shapiro Louis

    4 - STERIS plc (0001757898) (Issuer)

    8/12/25 5:27:39 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STERIS Announces Chief Financial Officer Transition

    Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton,  Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Michael J. Tokich, Senior Vice President and Chief Financial Officer (CFO), is stepping down from his role following seventeen years as CFO. The transition from Tokich to Karen L. Burton, currently Vice President and Chief Accounting Officer (CAO), will occur on August 18, 2025. Thereafter, Tokich will become Senior Financial Advisor, reporting to the CEO. "Mike's contributions over the past 25 years at STERIS have been instrumental in our growth and success," said Dan Care

    8/6/25 4:31:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Financial Results for Fiscal 2026 First Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the first quarte

    8/6/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Raises Dividend to $0.63 per share

    DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company's 20th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H

    7/30/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    SEC Filings

    View All

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    8/20/25 5:19:46 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    8/12/25 4:59:49 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    8/11/25 5:10:07 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    View All

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    STERIS Announces Changes to Board of Directors

    David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

    5/11/21 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Financials

    Live finance-specific insights

    View All

    STERIS Announces Chief Financial Officer Transition

    Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton,  Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Michael J. Tokich, Senior Vice President and Chief Financial Officer (CFO), is stepping down from his role following seventeen years as CFO. The transition from Tokich to Karen L. Burton, currently Vice President and Chief Accounting Officer (CAO), will occur on August 18, 2025. Thereafter, Tokich will become Senior Financial Advisor, reporting to the CEO. "Mike's contributions over the past 25 years at STERIS have been instrumental in our growth and success," said Dan Care

    8/6/25 4:31:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Financial Results for Fiscal 2026 First Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the first quarte

    8/6/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Raises Dividend to $0.63 per share

    DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company's 20th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H

    7/30/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/13/24 5:14:05 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:49:03 AM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:32:52 AM ET
    $STE
    Industrial Specialties
    Health Care